Cagrilintide 10mg

For research purposes only, this product is not intended for human consumption, diagnosis, or treatment. It has not been approved by the FDA or MHRA. Sales are limited to qualified researchers and institutions, and misuse could lead to account termination or legal consequences.

Good Product to stack with Reta or MJ 

Cagrilintide is a long-acting synthetic amylin analog peptide designed to reduce appetite and promote weight loss, often studied in combination with semaglutide.
Mechanism of Action
Cagrilintide is a synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells after meals. It acts as a dual amylin and calcitonin receptor agonist (DACRA), targeting the AMY1R, AMY2R, AMY3R, and calcitonin receptors in the brainstem regions that regulate satiety, gastric emptying, and glucagon secretion. Unlike GLP-1 receptor agonists, cagrilintide activates a distinct appetite pathway, signaling fullness and reducing food intake through the hindbrain.

Clinical Benefits
In clinical trials, cagrilintide alone produced an average 11.8% body weight loss over 68 weeks with fewer gastrointestinal side effects than GLP-1 drugs. When combined with semaglutide (as CagriSema), it achieved 22.7% weight loss, with nearly a quarter of participants losing 30% or more of their total body weight, representing one of the most effective obesity drug regimens tested. The combination leverages two independent satiety pathways, enhancing efficacy without overlapping mechanisms.


Dosing and Administration
Cagrilintide has a prolonged half-life of approximately 7–8 days due to structural modifications, including a fatty acid side chain, allowing once-weekly subcutaneous injections. In combination therapy, it is typically administered alongside semaglutide in a fixed-ratio formulation for weekly dosing.